OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecasts to 2026
Growth hormone deficiency (GHD) is a rare endocrine disorder characterized by inadequate secretion of growth hormone (GH), also called Somatropin, from the anterior pituitary gland located at the base of the brain (NORD, 2016). It is a heterogeneous disorder that may present in childhood as childhood GHD or later in adult life as adult GHD (AGHD) (Child et al., 2016; Molitch et al., 2011; Yuen, 2016). AGHD can be a progression from childhood, called childhood-onset GHD (COGHD), or start in adulthood, adult-onset GHD (AOGHD). The diagnosis of the disease consists of a number of tests; however, due to the lack of standard diagnostic criteria, the prevalence and incidence data vary widely and diagnosis is often delayed. In children, GHD is mostly identified through growth monitoring and is confirmed by a number of tests including insulin tolerance test (ITT), GH-releasing hormone (GHRH)-arginine test, clonidine stimulation test, glucagon stimulation test, and levodopa stimulation test (Stanley et al., 2012).
It is estimated that the 2016 sales for the GHD market at approximately $1.42B across the seven major pharmaceutical markets (7MM), which contains the US, the five majorEuropean markets (5EU: France, Germany, Italy, Spain, and UK), and Japan. By 2026, GlobalData expects the overall market to grow at a moderate Compound Annual Growth Rate (CAGR) of 3.9% to reach sales of $2.08B over the 10-year period.
The US market is anticipated to grow the fastest of the three regions, recording a CAGR of 4.4%, while the 5EU and Japan will each record CAGRs of 2.8% and 2.6%, respectively. At the end of 2026, the US will contribute 69.1% of global sales, while the 5EU and Japan will account for 16.1% and 14.8% of sales, respectively. The higher sales numbers for the US can be attributed mainly to the higher price of pharmaceuticals and the greater diagnosed prevalence of GHD in the country.
Growth Hormone Deficiency (GHD) market is highly fragmented and consists of seven brands of recombinant growth hormones (rGHs) administered as daily injections to patients. Among these drugs, the top four revenue generators for 2016 were Novo Nordisk’s Norditropin, Pfizer’s Genotropin, Eli Lilly’s Humatrope, and EMD/Merck Serono’s Saizen, contributing 48%, 15%, 10% and 10% of global sales, respectively. The forecast period from 2016-2026 will be marked by the expirations of the formulation patents for Norditropin, but this loss of patent exclusivity will not have much effect on the sales of the drug, considering previous trends in the market.
The report OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecasts to 2026 provides overview of GHD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
In particular, this report provides the following -
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook